Want to join the conversation?
$ARNA 2Q15 Call: ARNA is prepared for a start later this year of its multiple ascending dose study of APD371, a highly selective and potent cannabinoid 2 (CB2) receptor agonist in development for the treatment of pain. Phase 1 single ascending dose study showed excellent tolerability.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.